Materials and methods to potentiate cancer treatment

Details Materials and methods to potentiate cancer treatment Materials and methods to potentiate cancer treatment

2007-02-20

2007-02-20

Kifle, Bruck (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Chalcogen in the nitrogen containing substituent

C544S178000

Reexamination Certificate

active

09941897

ABSTRACT:
Compounds that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.

REFERENCES:
patent: 3904631 (1975-09-01), Elslager et al.
patent: 4003699 (1977-01-01), Rose et al.
patent: 4161589 (1979-07-01), Baumann et al.
patent: 4410708 (1983-10-01), Yahagi et al.
patent: 4451462 (1984-05-01), Wenk et al.
patent: 4539412 (1985-09-01), Archer
patent: 4558043 (1985-12-01), Wenk et al.
patent: 4904798 (1990-02-01), Kranz et al.
patent: 5401739 (1995-03-01), Ohno et al.
patent: 6174887 (2001-01-01), Haruta et al.
patent: 6297242 (2001-10-01), Hlasta
patent: 6407092 (2002-06-01), Hester et al.
patent: 6555593 (2003-04-01), Hoyle et al.
patent: 6589984 (2003-07-01), Naniwa et al.
patent: 2001/0027210 (2001-10-01), Wilson
patent: 27 37 207 (1979-03-01), None
patent: 29 22 488 (1980-12-01), None
patent: 29 50 291 (1981-06-01), None
patent: 31 41 970 (1983-05-01), None
patent: 44 24 712 (1996-01-01), None
patent: 0 078 241 (1983-05-01), None
patent: 0 106 800 (1984-04-01), None
patent: 0 107 620 (1984-05-01), None
patent: 0 342 665 (1989-11-01), None
patent: 0 471 516 (1992-02-01), None
patent: 1 355 173 (1964-03-01), None
patent: 8 298 (1970-11-01), None
patent: 2109373 (1983-02-01), None
patent: 2326410 (1998-12-01), None
patent: 55-44830 (1980-03-01), None
patent: 11 106371 (1999-04-01), None
patent: 11-199565 (1999-07-01), None
patent: 2002-97382 (2002-04-01), None
patent: WO 90/14008 (1990-11-01), None
patent: WO 92/16517 (1992-10-01), None
patent: WO 92/20666 (1992-11-01), None
patent: WO 95/20652 (1995-08-01), None
patent: WO 96/16632 (1996-06-01), None
patent: WO 96/22077 (1996-07-01), None
patent: WO 97/08133 (1997-03-01), None
patent: WO 97/31891 (1997-09-01), None
patent: WO 98/13502 (1998-04-01), None
patent: WO 99/14212 (1999-03-01), None
patent: WO 99/29705 (1999-06-01), None
patent: WO 99/39247 (1999-08-01), None
patent: WO 99/46262 (1999-09-01), None
patent: WO 00/00644 (2000-01-01), None
patent: WO 00/17386 (2000-03-01), None
patent: WO 00/18750 (2000-04-01), None
patent: WO 01/17985 (2001-03-01), None
patent: WO 02/20500 (2002-03-01), None
Eiden et al. (Archiv der Pharmazie (Weinheim, Germany) (1985), 318(4), 328-40).
Brown et al. (Can. J. Research (1948), 26D, 177-87). Abstract.
Gilman et al. (Journal of the American Chemical Society (1952), 74, 3027-9). Abstract.
Cretcher et al. (Journal of the American Chemical Society (1925), 47 , 163-6).
Elslager et al. (Journal of Medicinal Chemistry (1970), 13(3), 370-376).
Langer et al. (Monatshefte fuer Chemie (1959), 90, 623-33). Abstract.
Effenberger et al. (Chemische Berichte (1972), 105(6), 1926-42). Abstract.
Izzard et al.,J. Cancer Research, 59, pp. 2581-2586 (1999).
Russell et al.,J. Cancer Research, 55, pp. 1639-1642 (1995).
Powell et al.,J. Cancer Research, 55, pp. 1643-1648 (1995).
Araki et al.,Proc. Natl. Acad. Sci., USA, vol. 94, pp. 2438-2443 (1997).
Blunt et al.,Proc. Natl. Acad. Sci., USA, vol. 93, pp. 10285-10290 (1996).
Peterson et al.,Proc. Natl. Acad. Sci., USA, vol. 92, pp. 3171-3174 (1995).
Blunt et al.,Cell, vol. 80, pp. 813-823 (1995).
Biedermann et al.,Proc. Natl. Acad. Sci., USA, vol. 88, pp. 1394-1397 (1991).
Hendrickson et al.,Proc. Natl. Acad. Sci., USA, vol. 88, pp. 4061-4065 (1991).
Fulop et al.,Nature, vol. 347, pp. 479-482 (1990).
Christodouopoulos et al.,Cancer Research, 58, pp. 1789-1792 (1998).
Jackson,Int. J. Biochem. Cell Biol., vol. 29, No. 7, pp. 935-938 (1997).
Daniel et al.,Science, vol. 284, pp. 644-647 (1999).
M. Windholz (Ed.) et al., “The Merck Index, ninth edition,” p. 84, No. 658; p. 159, No. 1229; p. 187, No. 1458; p. 193, No. 1500; p. 263, No. 2050; p. 474, No. 3550; p. 680, No. 5043; p. 847, No. 6342; p. 871, No. 6521; p. 936, No. 7009; p. 939, No. 7031; p. 1069, No. 8011; p. 1080, No. 8094; p. 1275, No. 9592; 1976, Rahway, N. J.
Abadi, A.H., et al., “Synthesis, Antitumor and Antitubercular Evaluation of Certain New Xanthenone and Acridinone Analogs,”Arzneim.-Forsch./Drug Res.49 (I), Nr. 3, pp. 259-266 (1999).
Agasimundin, Y.S., et al., “Furano compounds. XX. Synthesis of angular and linear furoxanthones,”Journal fuer Praktische Chemie(Leipzip) (1972), 314(3-4), pp. 507-514, Abstract.
Croisy-Delcey, M., et al., “Aza Analogues of Lucanthone: Synthesis and Antitumor and Bactericidal Properties,”J. Med. Chem.(1983), 26, pp. 1329-1333.
Fonteneau, N., et al., “Synythesis of quinone and xanthone analogs of rhein,”Tetrahedron57 (2001) pp. 9131-9135.
Fujioka, H., et al., “Activities of New Acridone Alkaloid Derivatives against Plasmodium yoelii in vitro,”Arzneim.-Forsch./Drug Res.40 (II), Nr. 9 (1990), pp. 1026-1029.
Ghosh, C.K., et al., “Benzopyrans. Part 30. Synthesis of Substituted Xanthones from 3-Acyl-2-methyl-1-benzopyran-4-ones,”Tetrahedronvol. 49, No. 19, pp. 4127-4134, 1993.
Goud, A.N., et al., “Furan compounds. XVI,”Monatsh. Chem.(1969), 100(1), pp. 38-41, Abstract.
Harfenist, M., et al., “Selective Inhibitors of Monoamine Oxidase. 3. Structure-Activity Relationship of Tricyclics Bearing Imidazoline, Oxadiazole, or Tetrazole Groups,”J. Med. Chem.1996, 39, pp. 1857-1863.
Klopman, G., et al., “An artificial intelligence approach to the study of the structural moieties relevant to drug-receptor interactions in aldose reductase inhibitors,”Molecular Pharmacology(1988), 34(6), pp. 852-862, Abstract.
Mari, S., et al., “Flavone and xanthone derivatives related to fluoroquinolones,”II Farmaco54 (1999) pp. 411-415.
Tabarrini, O., et al., “Design and Synthesis of Modified Quinolones as Antitumoral Acridones,”J. Med. Chem., 1999, vol. 42, No. 12, pp. 2136-2144.
Xuan, T., et al., “Two new O-and C-glycosylxanthones from the Gentiana tizuensis Franch,”Gaodeng Xuexiao Huaxue Xuebao(2001), 22(10, Suppl.), pp. 148-150, Abstract.
Effenberge, F. et al., “Aminobenzenes. VIII. Rearrangement of phenyl carbamates. Syntheses of 2,4-dioxo-3,4-dihydro-2H-1,3-benzoxazines and salicylamides,” Chemische Berichte 1972, 105(6), 1926-42.

Affiliated with

Also associated with

Rating

Materials and methods to potentiate cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Materials and methods to potentiate cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods to potentiate cancer treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3843879